Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
Open Access
- 2 October 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (19) , 5885
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) share several pathophysiological mechanisms. While the prevalence of MASLD has been extensively studied in PCOS populations, the occurrence of PCOS among female adolescents with transient elastography (TE)-confirmed MASLD in pediatric hepatology settings remains poorly characterized. This cross-sectional study aims to address this knowledge gap and elucidate potential clinical and biochemical differences between female adolescents with MASLD and comorbid PCOS compared to those without PCOS. Methods: The study cohort included 45 female adolescents with TE-diagnosed MASLD. Comparative analyses of clinical and laboratory parameters were performed between those with (n = 19) and those without (n = 26) comorbid PCOS, diagnosed according to the Rotterdam criteria. Results: Adolescents with MASLD and comorbid PCOS exhibited significantly higher weight, lower height, and increased waist circumference compared to those without PCOS. Additionally, the prevalence of acanthosis nigricans was significantly higher in the PCOS group (68.4% versus 34.6%, p = 0.025). Regarding laboratory parameters, serum phosphorus levels and liver enzymes—including aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase—were significantly lower in adolescents with comorbid PCOS. However, no significant differences were observed in lipid profiles, glucose metabolism, or novel non-invasive biomarkers of MASLD. Conclusions: This study reveals distinct clinical and biochemical profiles in female adolescents with MASLD and comorbid PCOS compared to those without PCOS. These findings have the potential to inform and refine future screening protocols and diagnostic algorithms for these interrelated conditions, specifically tailored to pediatric hepatology settings.Keywords
Funding Information
- Recep Tayyip Erdogan Üniversitesi (02024008019030)
This publication has 38 references indexed in Scilit:
- Nonalcoholic Fatty Liver Disease in Young Children with ObesityChildhood Obesity, 2023
- Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry studyChinese Medical Journal, 2023
- Non‐alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: A systematic review and meta‐analysisJGH Open, 2021
- Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral ObesityNature Reviews Endocrinology, 2020
- Fibroblast growth factor 21 in non-alcoholic fatty liver diseaseMetabolism, 2019
- Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver diseaseThe Journal of Steroid Biochemistry and Molecular Biology, 2019
- Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysisJournal of Endocrinological Investigation, 2017
- Activity of LPO Processes in Women with Polycystic Ovarian Syndrome and InfertilityBulletin of Experimental Biology and Medicine, 2017
- Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric PatientsThe Journal of Pediatrics, 2016
- Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profileFertility and Sterility, 2013